Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2013

01.12.2013 | editorial

Neurooncology: current findings and challenges for the future

verfasst von: Silvia Hofer, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Excerpt

Primary central nervous system (CNS) tumors comprise approximately of 120 histological subtypes. Thus, it seems reasonable to concentrate primarily on some common entities. Most primary CNS tumors of adults are of glial origin and if they belong to WHO grade II–IV, they diffusely infiltrate the normal brain ab initio, i.e., pre-therapeutically. With current standard treatment they cannot be cured. And, here lies an immense challenge for the neurooncology community. …
Literatur
1.
Zurück zum Zitat Louis D, Ohgaki H, Wiestler O, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathologica. 2007;114:97–109 Louis D, Ohgaki H, Wiestler O, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathologica. 2007;114:97–109
2.
Zurück zum Zitat Cairncross G, Wang M, Shaw E. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;20, 31(3):337–43 Cairncross G, Wang M, Shaw E. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;20, 31(3):337–43
3.
Zurück zum Zitat van den Bent MJ,BAA van, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;20, 31(3):344–50 van den Bent MJ,BAA van, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;20, 31(3):344–50
4.
Zurück zum Zitat Wick W, Platten M, Meisner C, et al. NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer SocietyNOA 08. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707–15 Wick W, Platten M, Meisner C, et al. NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer SocietyNOA 08. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707–15
5.
Zurück zum Zitat Malmström A, Grønberg BH, Marosi C, et al. Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–26 Malmström A, Grønberg BH, Marosi C, et al. Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–26
6.
Zurück zum Zitat Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Lichter P, Taylor MD, Pfister SM. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012;12(12):818–34 Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Lichter P, Taylor MD, Pfister SM. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012;12(12):818–34
7.
Zurück zum Zitat Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A,European Organisation for Research and Treatment of Cancer Brain Tumour Group, EORTC Radiotherapy Group, National Cancer Institute of Canada Clinical Trials Group. Health-related quality of life in patients with glioblastoma: a randomized controlled trial. Lancet Oncol. 2005;6(12):937–44 Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A,European Organisation for Research and Treatment of Cancer Brain Tumour Group, EORTC Radiotherapy Group, National Cancer Institute of Canada Clinical Trials Group. Health-related quality of life in patients with glioblastoma: a randomized controlled trial. Lancet Oncol. 2005;6(12):937–44
Metadaten
Titel
Neurooncology: current findings and challenges for the future
verfasst von
Silvia Hofer, MD
Publikationsdatum
01.12.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0091-y

Weitere Artikel der Ausgabe 4/2013

memo - Magazine of European Medical Oncology 4/2013 Zur Ausgabe